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Abstract Activation of microglia/macrophages is important
in neonatal hypoxic–ischemic (HI) brain injury. Based on
experimental studies, we identified macrophage/microglia-de-
rived mediators with potential neurotoxic effects after neona-
tal HI and examined them in cerebrospinal fluid (CSF) from
newborn infants after birth asphyxia. Galectin-3 is a novel
inflammatory mediator produced by microglia/macrophages.
Galectin-3 is chemotactic for inflammatory cells and activates
nicotinamide adenine dinucleotide phosphate (NADPH) oxi-
dase resulting in production and release of reactive oxygen
species (ROS). Matrix metalloproteinase-9 (MMP-9) is a
tissue-degrading protease expressed by activated microglia
in the immature brain after HI. Both galectin-3 and MMP-9
contribute to brain injury in animal models for neonatal HI.
Quinolinic acid (QUIN) is a neurotoxic N-methyl-D-aspartate
(NMDA) receptor agonist also produced by activated micro-
glia/macrophages. Galectin-3 and MMP-9 were measured by
ELISA and QUIN by mass spectrometry. Asphyxiated infants
(n020) had higher levels of galectin-3 (mean (SEM) 2.64
(0.43) ng/mL) and QUIN (335.42 (58.9) nM) than controls
(n015) (1.36 (0.46) ng/mL and 116.56 (16.46) nM, respec-
tively), p<0.05 and p<0.01. Infants with septic infections (n0
10) did not differ from controls. Asphyxiated infants with
abnormal outcome had higher levels of galectin-3 (3.96
(0.67) ng/mL) than those with normal outcome (1.76 (0.32)
ng/mL), p00.02, and the difference remained significant in
the clinically relevant group of infants with moderate enceph-
alopathy. MMP-9 was detected in few infants with no differ-
ence between groups. The potentially neurotoxic macrophage/
microglia-derived mediators galectin-3 and QUIN are in-
creased in CSF after birth asphyxia and could serve asmarkers
and may contribute to injury.
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Introduction
Birth asphyxia with hypoxic–ischemic (HI) brain injury is
an important cause of permanent neurological and cognitive
impairment in newborn infants [1]. The immunoinflamma-
tory system is activated in the secondary neurotoxic cascade
after HI [2, 3] and microglial cells may contribute to peri-
natal brain injury [4–6]. Exposure to intrauterine inflamma-
tion also increases the risk for cerebral palsy in term infants
and may contribute to encephalopathy and to susceptibility
to asphyxiating factors [6–8]. It has been suggested that
activated microglial cells cause brain injury through the
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production of proinflammatory cytokines [3, 9, 10], excito-
toxins [11, 12], and reactive oxygen species (ROS) [13], but
the direct mechanisms by which inflammatory cell activa-
tion contributes to injury after neonatal HI are not fully
elucidated.
Galectin-3 is a β-galactoside-binding lectin, important in
cell adhesion, cell proliferation, and apoptotic regulation. In
recent years, it has also been demonstrated that galectin-3 is
involved in the inflammatory process. Galectin-3 is pro-
duced by activated tissue macrophages [14] including
microglial cells [15]. The mRNA expression is increased
10–20-fold after experimental neonatal HI [16] and there is
a massive staining for galectin-3 in activated microglia
adjacent to injury after HI in newborn mice [17]. Galectin-
3 is involved in phagocyte recruitment and activation after
inflammation [18, 19], has strong chemotactic properties for
monocytes and macrophages [20], and activates nicotin-
amide adenine dinucleotide phosphate (NADPH) oxidase
in primed inflammatory cells leading to the production and
release of ROS [14, 21]. Galectin-3 is also important in the
regulation of macrophage phenotypes by driving cell pop-
ulations towards an alternative activation associated with a
more chronic, reparative inflammation [22]. The dual role of
galectin-3 is reflected by conflicting results in adult and
neonatal brain injury models. In the adult stroke model,
galectin-3 is protective [23] while our previous studies show
that galectin-3 contributes to brain injury after neonatal HI
[17]. Galectin-3 activation and release has not been studied
in association with brain injury in the clinical setting.
The immature brain is highly susceptible to excitotoxins
acting on the N-methyl-D-aspartate (NMDA) receptor [24].
Quinolinic acid (QUIN) is a neurotoxic metabolite of L-
tryptophan that is used to produce experimental neuronal
injury [25]. QUIN acts mainly as a NMDA receptor agonist
[25] but can also induce ROS formation and oxidative injury
[26]. QUIN is produced by activated microglia/macro-
phages [11, 12, 27] and the synthesis is promoted by proin-
flammatory cytokines [28]. QUIN levels in injured brain
regions increase 2–4 days after insult in models of transient
ischemia [27, 29] and QUIN inhibition attenuates ischemic
injury in adult brain [30]. Cerebrospinal fluid (CSF) QUIN
concentrations are elevated in various inflammatory and non-
inflammatory cerebral diseases also in the pediatric population
[31] but have not previously been studied in neonatal HI injury.
Microglial cells are also the main source of matrix metal-
loproteinase (MMP)-9 in the immature brain [32]. MMP-9
contributes to injury and breakdown of the blood–brain
barrier (BBB) after experimental neonatal HI [32].
Although several studies indicate that inflammation and
activation of microglia/macrophages are detrimental after
HI, there is conflicting data in models of perinatal injury
[4, 33] and reports of protective microglial effects in adult
models of ischemia–reperfusion [34]. A more detailed
knowledge of inflammatory mechanisms that promote inju-
ry or repair is needed.
In this study, we focus on potentially neurotoxic micro-
glia/macrophage-derived inflammatory mediators identified
in experimental studies. We evaluate CSF concentrations of
galectin-3, QUIN, and MMP-9 after birth asphyxia and
correlate the levels to clinical symptoms, prognosis, and
long-term outcome. We also evaluate if systemic inflamma-
tion in the absence of asphyxia could induce elevated in-
flammatory markers in CSF.
Methods
Patients
Forty-five newborn infants treated at The Queen Silvia Child-
ren's Hospital were included in the study. The group was
divided into birth asphyxia (n020), systemic infection/inflam-
mation (n010), and controls (n015). The asphyxiated infants
fulfilled the following criteria: (1) intrapartum distress with
cardiotochographic late decelerations >1 h, absent variability
or bradycardia >30 min, early passage of thick meconium or
scalp pH <7.2. A small number of infants delivered after
severe obstetric complications (acute placental abruption or
uterine rupture) did not meet the intrapartum criteria. (2) Need
for neonatal resuscitation with positive pressure ventilation
>3 min, APGAR score ≤6 at 5′ or umbilical/first postnatal pH
<7.0, and/or base deficit >16. The samples were obtained
before hypothermia was introduced as a routine method and
none of the infants were thus cooled.
The asphyxia group was further divided into mild (hy-
peralert, irritable, normal, or increased tone), moderate (le-
thargic, decreased tone, seizures), or severe (comatose,
flaccid, failure to maintain ventilation, seizures not manda-
tory) encephalopathy [35, 36]. Infants were followed up by
a trained pediatrician for ≥18 months and referred to a child
neurologist and/or neuropsychologist if neurological abnor-
malities or developmental delay was suspected. An abnor-
mal outcome was defined as death, cerebral palsy, mental
retardation determined by WISC-III, or Griffith's standard-
ized tests and/or epilepsy.
To evaluate the contribution of systemic inflammation to
elevated inflammatory mediators in CSF, a subgroup of
infants with clinical signs of sepsis but no signs of asphyxia
was used (n010). All infants had CRP >100 mg/L and 6/10
included infants also had positive blood cultures. The con-
trol infants consisted of infants with clinical suspicion of
infection but with negative bacterial cultures in blood and
CSF in addition to CRP <50 mg/L (n015). The highest CRP
value within 24 h before or after the spinal tap was used.
Infants with intracranial hemorrhage, cerebral malforma-
tion, elevated white blood cell count, or positive viral/bacterial
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cultures in CSF were excluded from all groups. Samples were
also excluded if containing macroscopic blood.
CSF Sampling
CSF was obtained by spinal taps for diagnostic purposes.
After 1.5 mL for clinical use had been tapped, ≤1.5 mL of
CSF was collected and spun at 4,000 rpm for 10 min. Cell
counts and CSF protein were analyzed as clinical routine
samples. Samples were stored at −80 °C until analysis. Due
to limited sample volumes, all compounds were not ana-
lyzed in every patient. Galectin-3 and MMP-9 were ana-
lyzed in 15/20 asphyxiated infants, 11/15 controls, and 8/10
infections. QUIN was analyzed in 18/20 asphyxias, 12/15
controls, and 10/10 infections. Parental consent was
obtained and the study was approved by the Research Ethics
Committee, Sahlgrenska University Hospital.
Galectin-3 and MMP-9 Analyses
Concentrations of galectin-3 and MMP-9 were measured
using quantitative enzyme-linked immunosorbent assay
(ELISA) according to the manufacturers' instructions. The
detection level for the galectin-3 ELISA (BMS279; Bender
MedSystems) was 0.150 ng/mL, while the MMP-9 (total)
ELISA (Quantikine® DMP900; R&D Systems) detected
MMP-9 (both 92 kDa pro- and 82 kDa active forms) con-
centrations down to 0.156 ng/mL.
QUIN Analysis
CSF QUIN was measured as the dihexafluoroisopropanol
ester by electron impact negative chemical ionization mass
spectrometry and gas chromatography with [13C7]-QUIN as
internal standard [37].
Statistical Analysis
Results are given as mean (SEM). Groups were compared
using the Kruskal–Wallis or the Mann–Whitney U test. The
Kruskal–Wallis test was used with Dunn's correction when
appropriate. Correlations were analyzed with Spearman's
rank test and a p value <0.05 was considered statistically
significant.
Results
Inflammatory Mediators in Asphyxiated Infants and Infants
with Systemic Infection
Background data are given in Table 1. Severe obstetric
complications (abruptio placentae, uterine rupture, dystocia,
or tight nuchal cord) was present in 9/20 deliveries, while
only one mother had clinical signs of chorioamnionitis.
Asphyxiated infants had significantly higher levels of
galectin-3 (mean (SEM) 2.64 (0.43) ng/mL) (n015) com-
pared to control infants (1.36 (0.46) ng/mL) (n011), p<
0.05, while the levels in infants with infections (1.36
(0.47) ng/mL) (n08) did not differ from controls (Fig. 1).
The same pattern was seen for QUIN, with increased
concentrations in asphyxiated infants (335.42 (58.9) nM)
(n018) vs. controls (116.56 (16.46) nM) (n012), p<0.01,
while the concentrations in infants with systemic infection
(140.92 (22.8) nM) (n010) were similar to controls (Fig. 1).
In a subanalysis, infected infants with positive cultures (n0
6) were compared with control infants and no differences
were found for either galectin-3 or QUIN. MMP-9 was
detected in only one infant with severe asphyxia.
Inflammatory Mediators in Relation to Encephalopathy
and Prognosis
The distribution of galectin-3 and QUIN concentrations
according to encephalopathy is demonstrated in Fig. 2. Sta-
tistical comparisons were not performed due to the uneven
number of patients in the different groups.
Infants with poor prognosis based on a severe clinical
course (moderate and severe encephalopathy) had significant-
ly higher concentrations of galectin-3 (3.08 (0.45) ng/mL) and
QUIN (388.5 (69.4) nM) than infants with milder clinical
symptoms and a predicted good prognosis (mild encephalop-
athy, controls, infections) (1.21 (0.25) ng/mL and 130.6 (12)
nM), p<0.0001 and p<0.0001, respectively (Fig. 3).
Inflammatory Mediators and Outcome
An abnormal outcome was found in 8/20 asphyxiated
infants, including one infant who died in the neonatal peri-
od. Cerebral palsy of the bilateral spastic or dyskinetic type
was found in 4/7, mental retardation in 3/7, and severe
epilepsy in 2/7 surviving infants. Asphyxiated infants with
abnormal outcome had higher levels of galectin-3 (3.96
(0.67) ng/mL) (n06) than those with normal outcome
(1.76 (0.32) ng/mL) (n09), p00.02. QUIN levels were
higher (435.7 (88.9) nM) (n08) in infants with an abnormal
vs. those with a normal (255.2 (72.7) nM) (n010) outcome,
but the difference did not reach statistical significance
(Fig. 4). Infants with septic infections and control infants
had all normal outcome.
Within the group of infants with moderate encephalopa-
thy (n012), where prognosis is hard to predict based on
clinical signs, infants with abnormal outcome had higher
levels of galectin-3 (4.81 (0.64) ng/mL) (n04) than those
with normal outcome (2.19 (0.36) ng/mL) (n06), p00.02.
No difference in QUIN concentrations was seen (Fig. 5).
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Clinical Correlations
There was a significant correlation between galectin-3 and
QUIN levels, p00.01. Concentrations of QUIN and galectin-
3 did not correlate with CRP, CSF protein, or age at lumbar
puncture in the whole group or in the subgroups.
Discussion
In this study, we found increased concentrations of QUIN
and galectin-3 in CSF from asphyxiated infants. These
increases were more pronounced in infants with severe
clinical course and poor prognosis. Galectin-3 was also
elevated in asphyxiated infants with abnormal outcome
and the elevation remained significant within the clinically
important group with moderate encephalopathy. Systemic
infection/inflammation without signs of asphyxia did not
result in elevated CSF concentrations.
The pathogenesis of birth asphyxia is complex and sev-
eral other factors including chorioamnionitis may contribute
to neonatal encephalopathy as well as perinatal brain injury
[7, 8]. In order to define a group where perinatal asphyxia
was indeed the probable cause of encephalopathy, we used
well-established criteria including signs of fetal distress,
neonatal need for resuscitation, and most importantly, met-
abolic acidosis. Previous studies show that a large propor-
tion of encephalopathic infants fulfilling very similar criteria
for asphyxia have acutely evolving injuries on magnetic
resonance imaging (MRI) [38], suggesting that the insult
took place at or near the time of birth. In addition, nearly
half of the asphyxiated infants in our study were exposed to
severe obstetric complications that may directly impair oxy-
gen delivery and they presented with a considerable metabolic
acidosis (mean pH 6.9 and base deficit 20). In clinical inter-
vention studies using hypothermia, eligible infants with mod-
erate to severe encephalopathy have to meet inclusion criteria
for significant birth asphyxia (pH <7, base deficit >16, low
APGAR score at 10′ or prolonged need for resuscitation) [39,
40]. Seventeen out of 20 asphyxiated infants in our study
fulfilled these criteria even if our study also included infants
with mild encephalopathy. The infants with adverse outcome
also met the internationally accepted clinical criteria for cere-
bral palsy caused by an acute intrapartum event [41].
Blood gases were not routinely obtained at birth in the then
apparently healthy infection and control infants. Since isolated
metabolic acidosis is a common clinical finding not associated
Table 1 Background data
Results are given as mean
(SEM), and statistical analysis
was performed with Kruskal–
Wallis test. Acidosis was evalu-
ated in umbilical cord blood or
first postnatal sample. Early
blood gases were not routinely
analyzed in control or infected
infants
Asphyxia (n020) Systemic infection (n010) Control (n015)
Gestational age (weeks) 39.14 (0.66) 39.60 (0.71) 39.8 (0.48) NS
Sex (male/female) 8/12 8/2 12/3
APGAR score at 5 min 3.85 (0.61) 9.50 (0.40) 9.20 (0.22) p<0.0001




Age at LP (h) 37.70 (4.48) 37.00 (10.61) 64.13 (10.67) NS































Fig. 1 CSF concentrations of QUIN and galectin-3. The asphyxia
group (n020) had significantly higher concentrations of QUIN (p<
0.01) and galectin-3 (p<0.05) than the control group (n015), while the
infection group (n010) did not differ from controls (Kruskal–Wallis
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Fig. 2 CSF concentrations of QUIN and galectin-3 in asphyxiated
infants with mild (n04), moderate (n013), and severe (n03) enceph-
alopathy. Crossbars represent mean
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with neurological sequels in infants without encephalopathy,
the control and infected infants are likely to be a true low-risk
group even if early blood gases for comparisons with the
asphyxiated infants were not available.
Even if the study group fulfilled strict criteria for intra-
partum asphyxia, we cannot exclude that other factors in-
cluding chorioamnionitis contributed to the susceptibility to
asphyxia. Only one mother had clinical chorioamnionitis,
but placentas were not examined and subclinical infections
cannot be ruled out. However, the lack of microglia re-
sponse and CSF inflammatory reaction in infants with sys-
temic inflammation/infection makes it less likely that
chorioamnionitis in itself, or the systemic inflammation seen
in the asphyxiated infants, could explain the CSF changes
found in infants with encephalopathy.
QUIN in CSF has previously been studied under normal as
well as various pathological conditions in the pediatric popu-
lation [42, 43], but there are no studies in newborns or after HI
brain injury. The normal QUIN levels are inversely related to
age with a mean concentration of 31 nM (range 20–64) in
infants below 1 year of age [42]. We report significantly
higher levels in newborn control infants with a mean concen-
tration of 116 nM. This increase may be due to the trauma of
normal labor or be part of the mild inflammatory activation
associated with normal birth. The latter seems less likely since
infants with a pronounced systemic inflammatory response
included in this study did not differ from controls. In asphyx-
iated infants, QUIN concentrations were elevated approxi-
mately threefold, and the concentrations were similar to
those previously found in infants with intraventricular hemor-
rhage [43], a clinical condition that is associated with an
intense and prolonged inflammatory response in CSF [44].
QUIN concentrations were also associated with a severe
clinical course and poor prognosis, but the differences be-
tween asphyxiated infants with various outcomes did not
reach statistical significance. QUIN concentrations may,
however, be difficult to evaluate since timing is important
for the absolute value. In experimental ischemia, QUIN is
significantly elevated after 2 days and increases further
thereafter [29]. Serial CSF samples after trauma show an
increase in QUIN concentrations up to 48 h [45] and in-
creased QUIN levels were associated with mortality, when
corrected for time of sampling [45]. In our study, sampling
was performed at a mean of 38 h after birth in the asphyx-
iated group, suggesting that many infants had not reached
their peak levels and that the values may not fully reflect the
extent of injury. It is, however, not likely that the timing
could explain the difference between groups since there was
no difference in age at sampling between groups and no
correlation between QUIN levels and age at sampling. In
addition, there was a tendency towards later sampling in the
control group suggesting that the control levels might even































Fig. 3 CSF concentrations of QUIN and galectin-3 in asphyxiated
infants with good or poor prognosis. Infants with poor prognosis (n0
12/14) based on a severe clinical course (moderate and severe enceph-
alopathy) had significantly higher concentrations of galectin-3 and
QUIN (p<0.0001 and p<0.0001, Mann–Whitney U test) than infants
with milder clinical symptoms (n025) and a predicted good prognosis





























Fig. 4 CSF concentrations of QUIN and galectin-3 in asphyxiated
infants with normal (n012) or abnormal (n08) outcome. Galectin-3
levels were significantly higher in infants with abnormal outcome (p0

































Fig. 5 CSF concentrations of QUIN and galectin-3 in asphyxiated
infants with moderate encephalopathy and normal (n08) or abnormal
(n05) outcome. Galectin-3 levels were significantly higher in infants
with abnormal outcome (p00.02, Mann–Whitney U test). Crossbars
represent mean
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To our knowledge, galectin-3 has not previously been
measured in CSF from newborns or in association with brain
injury. We report detectable levels in all samples and a signif-
icant increase in asphyxiated infants and infants with a severe
clinical course, poor prognosis, and abnormal outcome. In a
separate analysis of the clinically important group of infants
with moderate encephalopathy, the difference in galectin-3
levels between infants with normal or abnormal outcome
remained significant although the number of infants was
small. Markers of abnormal outcome are of specific impor-
tance in this group since only 30–50 % of these infants
develop a permanent brain injury despite similar clinical
courses [1]. We have previously shown that in the experimen-
tal setting of neonatal HI, the effect, but not the expression, of
galectin-3 is gender-dependent [17]. In this study, the groups
were too small to allow for subgroup analyses, and we cannot
exclude that the uneven distribution of boys and girls in the
different study groups may have influenced the results.
The pattern of activation and CSF increases were similar
for QUIN and galectin-3 and the concentrations in individual
infants significantly correlated. This suggests that galectin-3
and QUIN are part of the same inflammatory response. The
galectin-3 pattern of increase and correlation to severity of
clinical course and outcome is also similar to that seen in
previous studies of proinflammatory cytokines [2].
MMP-9 was found in only one infant with severe as-
phyxia. This may be due to the detection method. Normal
CSF values are below the detection level of the ELISA used
[46] and even in severe CNS inflammatory disease, MMP-9
is detected in only a minority of patients [47].
An important question is whether galectin-3 and QUIN are
produced within the brain or if systemic cells of the monocyte/
macrophage lineage are responsible for the increase found in
CSF. Galectin-3 as well as QUIN are produced by activated
microglia–macrophages as part of the inflammatory response
after focal cerebral insults [11, 15, 27]. QUIN is produced by
local de novo synthesis after focal ischemia [48] but an
increased production of QUIN within the brain is also seen
in systemic inflammation [27, 49]. In experimental studies,
systemic inflammation induced by the bacterial toxin lipo-
polysaccharide (LPS) results in increased CSF concentrations
of QUIN [27, 49], but in patients with HIV, elevated serum
concentrations do not correlate with CSF levels, supporting an
intracerebral source of QUIN [50]. Galectin-3 activation in
focal vs. systemic inflammatory response is less well studied
and it is not known whether HI or sepsis result in a systemic
galectin-3 production.
Another possible mechanism by which systemically pro-
duced inflammatory mediators can contribute to elevated
CSF concentration is through leakage over an injured
BBB. Serum QUIN concentrations normally exceed those
found in CSF [50], while serum levels of galectin-3 under
normal or inflammatory conditions are not known. In our
study, CSF protein content did not differ between asphyxi-
ated infants and controls suggesting that there were no major
differences in BBB damage. The absence of correlation
between CSF protein and QUIN or galectin-3 concentra-
tions also suggests that BBB breakdown is not responsible
for the increased levels seen in CSF. CSF protein level was,
however, not analyzed in all samples (7/45 missing) and in
the absence of simultaneous blood samples, we cannot
exclude a systemic contribution. It is, however, likely that
brain microglia/macrophages are an important source of
CSF galectin-3 and QUIN after asphyxia. Increased expres-
sion of galectin-3 at mRNA [16] as well as protein [17] is
seen after experimental perinatal HI and intrathecal produc-
tion of QUIN with associated increases in CSF is seen in
experimental brain ischemia and inflammation [29, 48], as
well as clinical traumatic brain injury [31, 51].
Irrespective of their possible origins, both QUIN and
galectin-3 have possible neurotoxic effects. QUIN is a
well-known neurotoxin, acting as an NMDA receptor ago-
nist [25] as well as promoting oxidative injury [26]. Inhibi-
tion of QUIN production reduces injury in adult ischemia–
reperfusion injury [30], but the immature brain has not been
studied. Interestingly, studies in rats suggest that the imma-
ture brain has a specific sensitivity to QUIN with a maximal
vulnerability at postnatal day 7 when the brain maturity
closely resembles that seen in newborn infants [52]. In
addition, QUIN-induced ROS formation is dependent on
the presence of free ferrous iron [26]. Free iron is released
after experimental HI in newborn pigs [53] and is present in
CSF from asphyxiated infants [54]. QUIN is neurotoxic in
vitro in concentrations as low as 100 nM [55] and studies in
patients with encephalitis and intracerebral production of
QUIN show that QUIN concentrations in the brain is tenfold
higher than that found in CSF [50]. It is, thus, likely that
brain QUIN levels in the asphyxiated patient could reach
toxic levels.
Galectin-3 contributes to injury after experimental neo-
natal HI possibly by modulating the microglia response and
MMP-9 activation [17]. This is in stark contrast to findings
in adult stroke models where galectin-3 is expressed in a
microglia population with protective properties [56] and
transgenic mice lacking functional galectin-3 have aggra-
vated injury [23]. Galectin-3 may, thus, serve as a useful
marker of severity of injury in the newborn asphyxiated
infant, but further studies are needed to determine whether
galectin-3 contributes to injury also in the clinical setting.
In conclusion, our study demonstrates elevated levels of
macrophage/microglia-derived potentially neurotoxic in-
flammatory mediators in CSF from asphyxiated infants with
severe clinical course and adverse outcome. These media-
tors have been identified in experimental studies and our
study confirms their clinical relevance. In addition, the role
of microglia in HI injury is under current debate and a more
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detailed knowledge of inflammatory mechanisms that con-
tribute to injury or repair can, in the future, lead to targeted
therapeutic interventions.
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